P3 Health Partners (PIII) Q3 2025 Earnings
How Did PIII Stock React to Q3 2025 Earnings?
S&P 500 over the same 30 days: −0.08%.
Did PIII Beat Earnings? Q3 2025 Results
No. P3 Health Partners reported Q3 2025 earnings of $-9.67 a share on Nov 13, 2025, missing the $-6.04 consensus estimate by 60.2%. Revenue was $345.3M against a $346.6M estimate.
P3 Health Partners delivered a painful third-quarter miss, with its loss per share of $9.67 coming in 60.19% worse than the consensus estimate of $6.04, as unfavorable mid-year settlement adjustments weighed heavily on capitated revenue and dragged results well below expectations. Revenue slipped 4.7% year-over-year to $345.25 million, fractionally below the $346.64 million consensus, reflecting the company's intentional pruning of its membership base, which contracted roughly 10% to approximately 116,000 at-risk members as part of ongoing network and payer rationalization. While operating loss narrowed to $44.22 million from $106.99 million a year ago and medical margin improved to $4.41 million from just $540,000, surging interest expense of $20.53 million, up from $5.65 million, underscored the growing cost of the company's heavier debt load. Management revised full-year 2025 guidance to an adjusted EBITDA loss of $95 to $110 million on revenues of $1.40 to $1.45 billion, while pointing to $120 to $170 million in identified EBITDA expansion opportunities as its roadmap toward profitability in 2026.
- Expansion of Care Enablement Model driving positive momentum
- Intentional network and payer rationalization reducing at-risk membership by 10% year-over-year
- Per-member funding improved 6% year-over-year when adjusted for prior-period items
- Medical cost trends normalized for prior-year adjustments remained stable
- Premium deficiency reserve release of $23.7 million in Q3 2025
- Operating discipline strengthening across organization
“Our core business continues to demonstrate positive momentum in the third quarter, driven by the expansion of our Care Enablement Model. Medical cost trends, normalized for prior-year adjustments, remain stable, operating discipline is strengthening, and we're seeing continued traction in the markets where our model is most aligned. With the progress underway, we're confident in our ability to execute on the $120 to $170 million in EBITDA expansion opportunities identified, positioning us for sustainable profitability in 2026 and beyond.”
P3 Health Partners CEO, on the earnings call
What Was P3 Health Partners's Outlook in Q3 2025?
P3 revised its fiscal 2025 guidance: total revenues of $1,400 to $1,450 million; at-risk members of 112,000 to 117,000; medical margin of $67 to $82 million ($48 to $59 PMPM); and Adjusted EBITDA loss of $95 to $110 million. Management identified $120 to $170 million in EBITDA expansion opportunities and expressed confidence in achieving sustainable profitability in 2026 and beyond.
PIII YoY Financials
| Metric | Q3 2025 | Q3 2024 | Year over year |
|---|---|---|---|
| Revenue | $345.3M | $362.1M | −4.7% |
| Operating Income | −$44.2M | −$27.9M | +58.7% |
| Net Income | −$69.5M | −$137.1M | −49.3% |
PIII Revenue by Segment
Figures from SEC filings and company reports. Not investment advice.